<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565474</url>
  </required_header>
  <id_info>
    <org_study_id>LESTX-ES-01</org_study_id>
    <nct_id>NCT00565474</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant</brief_title>
  <official_title>A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled, 6-month Study to Establish the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vascular Graft Disease in de Novo Renal Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Principal objective is to investigate if the treatment with fluvastatin can prevent the
      progression of vascular graft disease in de novo renal transplant patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if treatment with fluvastatin can prevent the progression of vascular graft disease. The difference between the vascular intimal thickness measured on the baseline biopsy and the biopsy at the end of the study between the two treatment group</measure>
    <time_frame>three Yrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour creatinine and proteinuria values at 6 months post-transplant, graft survival and patient survival at 6 months, differences in lipid profile between the treatment groups, incidence of rejection episodes treated and documented by biopsy at 6</measure>
    <time_frame>Three yrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Graft Vasculopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fluvastatin 40mg b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatin</intervention_name>
    <description>Graft vasculopathy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients where the investigator expects to prescribe cyclosporine, mycophenolate
             mofetil and corticosteroids as base immunosuppressive therapy, regardless of their
             participation in the study.

          -  Man or woman aged from 17 to 70 years.

          -  Patients that receive a first or second renal transplant from a non-living donor

          -  Patients where allograft biopsies may be performed.

          -  Patients receiving an identical or compatible ABO graft.

          -  Patients willing to give their written informed consent to all study issues.

          -  Women with child-bearing potential should use a medically proven contraceptive method
             during the study.

          -  Patients able to meet all study requirements.

        Exclusion criteria:

          -  Patients with pre-transplant cholesterol levels above 240 mg/dl (6.2 mmol/l).

          -  Positive cross-match of T cells or ABO incompatibility with the donor.

          -  Recipients of multiorgan transplant.

          -  Patients with diabetes mellitus.

          -  HIV seropositive or with surface antigen of Hepatitis B .

          -  Kidney from a donor aged over 65 years.

          -  Last panel of reactive antibody (PRA) above 50%.

          -  Women who plan to get pregnant within 12 months, or who are pregnant and/or nursing.

          -  Patients with a history of cancer in the previous 5 years, except for patients
             successfully treated with localized carcinoma of squamous or basal cells of the skin,
             or cervix cancer in situ treated adequately.

          -  Patients receiving an investigational drug in the 30 days prior to the transplant
             and/or who will receive an investigational/non-registered drug during the study,
             except for the use of erythropoietin-stimulating products

          -  Patients with myocardial infarction within the 6 months prior to the transplant,
             uncontrollable cardiac arrhythmia or another severe or unstable medical condition
             probably affecting the safety of the patient or the study objectives.

          -  Patients with alcohol dependence or drug abuse not solved, or signs of organic lesion
             caused by alcohol, mental dysfunction or other factors limiting their ability to fully
             cooperate with the study.

          -  Patients where it is planned to perform an induction treatment with preparations
             containing antilymphocyte antibodies (ALG, ATG or OKT-3).

          -  Patients scheduled to receive cyclosporine i.v. for over 48 hours.

          -  Patients with liver dysfunction (ALT or AST values or total bilirubin 2 times above
             the upper limit of the normal ranges of the laboratory values).

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Serón D, Oppenheimer F, Pallardó LM, Lauzurica R, Errasti P, Gomez-Huertas E, Bosmans JL, Sanchez-Plumed J, Romero R, Marques M, Fulladosa X, Moreso F. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial. Transplantation. 2008 Jul 15;86(1):82-7. doi: 10.1097/TP.0b013e318174428d.</citation>
    <PMID>18622282</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2007</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal transplantation</keyword>
  <keyword>fluvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

